This ELISA kit provides quantitative measurement of IGFBP7 (insulin-like growth factor binding protein 7) in human samples, supporting research into its roles in cellular senescence, TGF-β signaling, and tumor suppression. Because IGFBP7 functions as both a secreted autocrine/paracrine factor and a circulating biomarker with concentrations that shift markedly between healthy and disease states, researchers need an assay that accommodates diverse sample contexts without extensive optimization.
Detection Range: The 31.25–2000 pg/mL range spans the concentrations typically observed in human serum and plasma, where circulating IGFBP7 levels can rise several-fold in renal injury, heart failure, and advanced malignancies. Most serum samples require minimal or no dilution, simplifying assay planning.
Sensitivity: At 15.6 pg/mL, the kit detects IGFBP7 in low-abundance conditions such as conditioned media from senescence-resistant cell lines or early-stage kidney injury samples where secreted levels are just emerging above baseline.
Sample Compatibility: Validation across serum, plasma, cell culture supernates, and tissue homogenates enables researchers to correlate circulating IGFBP7 with local tissue expression and in vitro secretion within a single study, critical for dissecting its paracrine versus endocrine functions.
Assay Efficiency: Requiring only 50–100 µL per well and 1–5 hours to complete, the kit accommodates limited clinical specimens and primary cell-conditioned media while supporting same-day results.
This kit is particularly suited for studies in acute kidney injury biomarker discovery, oncogene-induced senescence, and cardiac fibrosis research.